WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
Published . Updated .
The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.
Directly affected
Indirectly affected
- CPHI CHINA PHARMA HLDGS INC
GA selected CPHI as a RELATED security because its canonical security name directly matches this event's themes: pharma, china. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- CRDF CARDIFF ONCOLOGY INC COM
GA selected CRDF as a RELATED security because its canonical security name directly matches this event's themes: oncology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.
Source: BioPharma Dive
How far Astrazeneca (AZN) has moved since 15 Sep 2026
Since the first closing price after “WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight,” Astrazeneca (AZN) is +0.78%. The S&P 500 fund (SPY) is +1.66% over the same days, a -0.88% difference versus the market.
Official trades in Astrazeneca (AZN) around 15 Sep 2026
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Astrazeneca (AZN)
Companies tied to this story
- AZN Astrazeneca
Astrazeneca (AZN) is linked, with no stored direction, high confidence in the 15 Sep 2026 story “WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight.” Reason on file: The reported development directly names ASTRAZENECA PLC in the headline; GA resolved that company to AZN
- CPHI China Pharma Holdings
In “WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight,” China Pharma Holdings (CPHI) is linked, with no stored direction, medium confidence. Reason on file: GA selected CPHI as a RELATED security because its canonical security name directly matches this event's themes: pharma, china. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ACHC Acadia Healthcare
Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence in the 15 Sep 2026 story “WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight.” Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
For “WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence in the 15 Sep 2026 story “WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight.” Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
In “WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- CRDF Cardiff Oncology
In “WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight,” Cardiff Oncology (CRDF) is linked, with no stored direction, medium confidence. Reason on file: GA selected CRDF as a RELATED security because its canonical security name directly matches this event's themes: oncology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Astrazeneca (AZN)
On 15 Sep 2026, “WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight” is the story that connects Astrazeneca (AZN) to this story.
Astrazeneca (AZN) is on the page because The reported development directly names ASTRAZENECA PLC in the headline; GA resolved that company to AZN
A second company, China Pharma Holdings (CPHI), is listed for a different reason: GA selected CPHI as a RELATED security because its canonical security name directly matches this event's themes: pharma, china. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Price levels for Astrazeneca (AZN)
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. AZN traded between 154.83 and 169.73 across 20 sessions. The latest close on file is 164.02. CPHI traded between 0.64 and 1.28 across 20 sessions. The latest close on file is 0.67.
A simple score for Astrazeneca (AZN)
46 out of 100
“WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.